A maker of sterilization and infection-prevention products and services, STERIS supplies hospitals, medical device makers, and pharmaceutical plants with sterilizers, cleaning chemistries, and contract sterilization. It was founded in 1985 in Mentor, Ohio, as Innovative Medical Technologies by microbiologist Raymond Kralovic, who invented a low-temperature liquid sterilization process for delicate instruments like endoscopes that couldn't survive steam. Renamed STERIS in 1987 — a nod to "sterile" — its brands include V-PRO sterilizers and VAPROX HC sterilant.
STERIS shareholders elect nine directors and approve all seven proposals at 2026 Annual General Meeting.
At the July 31, 2026 Annual General Meeting, holders of 89,909,204 ordinary shares (92.25% of outstanding) were present, constituting a quorum.
Show detailsHide details
All nine director nominees were elected for one-year terms, with votes for ranging from 74,792,537 (Cynthia L. Feldmann) to 85,688,682 (Louis A. Shapiro).
Shareholders ratified Ernst & Young LLP as independent registered public accounting firm for fiscal year ending March 31, 2027 (82,976,444 for, 6,914,777 against).
Shareholders approved appointment of Ernst & Young Chartered Accountants as statutory auditor and authorized the Board/Audit Committee to set its remuneration.
Non-binding advisory approval of named executive officer compensation passed (77,639,271 for, 8,493,021 against), and renewals of authority to issue shares and opt out of pre-emption rights were approved.
Effective upon completion of the meeting, the board size was reduced to nine members.
5.07 Submission of Matters to a Vote of Security Holders
STERIS reports fiscal Q1 2027 revenue up 7% to $1.5 billion, adjusted EPS $2.59
Total revenue for the quarter ended June 30, 2026 increased 7% to $1.5 billion from $1.4 billion a year earlier; constant currency organic revenue growth was 6%.
Show detailsHide details
As reported diluted EPS rose to $2.04 from $1.79; adjusted diluted EPS increased to $2.59 from $2.34.
Healthcare segment revenue grew 8% to $1.05 billion; AST revenue increased 6% to $297.6 million; Life Sciences revenue rose 9% to $146.7 million.
The company announced a restructuring plan to consolidate formulated chemistries manufacturing into a new North Carolina Center of Excellence, with expected pre-tax charges of $55–70 million and completion by fiscal 2030.
Fiscal 2027 guidance reiterated: revenue growth of 7–8% as reported, 6–7% constant currency organic, and adjusted EPS of $11.10–$11.30; capital expenditures now expected at ~$450 million and free cash flow ~$800 million.
2.02 Results of Operations and Financial Condition · 2.05 Costs Associated with Exit or Disposal Activities · 9.01 Financial Statements and Exhibits
STERIS appoints Pierre Boulud to Board and Richard Breeden to retire
Richard C. Breeden notified STERIS on May 1, 2026, that he will not stand for reelection at the 2026 Annual General Meeting, with no disagreement with the Company.
Show detailsHide details
On May 5, 2026, the Board increased its size from nine to ten members and appointed Pierre Boulud as a director effective that date.
Pierre Boulud is CEO of bioMérieux, a biotechnology company focused on in vitro diagnostics, and has held that role since June 2023.
Mr. Boulud will receive a prorated fee of $76,989 for the remainder of the Board's 2025-26 term, payable in career restricted stock units under the Non-Employee Director Compensation Program.
The Company issued a press release on May 7, 2026, announcing the appointment, attached as Exhibit 99.1.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
STERIS reports fiscal Q3 2026 revenue up 9% to $1.5B, EPS $1.96, adjusted EPS $2.53
Total revenue from continuing operations increased 9% to $1.5 billion in the quarter ended December 31, 2025, compared with $1.4 billion in the prior-year quarter.
Show detailsHide details
As reported EPS from continuing operations was $1.96, up from $1.75 in the prior-year quarter; adjusted EPS was $2.53, up from $2.32.
Healthcare segment revenue grew 9% to $1.1 billion; AST revenue grew 11% to $286.6 million; Life Sciences revenue grew 7% to $145.8 million.
Fiscal 2026 outlook maintained: revenue growth of 8-9% as reported, constant currency organic growth of 7-8%, adjusted EPS of $10.15-$10.30.
Tariff impact on pre-tax profit is now estimated at approximately $55 million, up from prior expectations of approximately $45 million.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
STERIS reports Q2 FY2026 revenue up 10% to $1.5B, raises full-year outlook
Total revenue from continuing operations for Q2 FY2026 increased 10% to $1.5 billion, with constant currency organic revenue growth of 9%.
Show detailsHide details
As reported EPS from continuing operations was $1.94, up from $1.51 in the prior year quarter; adjusted EPS was $2.47, up from $2.14.
Healthcare segment revenue grew 9% to $1,033.8 million; AST revenue grew 10% to $281.5 million; Life Sciences revenue grew 13% to $145.0 million.
Free cash flow for the first half of fiscal 2026 was $527.7 million, up from $344.5 million in the prior year period.
Fiscal 2026 outlook raised: constant currency organic revenue growth now expected at 7-8%, adjusted EPS at $10.15-$10.30, and free cash flow at approximately $850 million.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
STERIS CFO Michael J. Tokich resigns; Karen Burton appointed CFO effective August 18, 2025.
Tokich will serve as senior financial advisor until March 31, 2026, with reduced base salary of $427,450.14.
Show detailsHide details
Michael J. Tokich resigned as Senior Vice President and CFO, effective with a Transition Agreement dated August 5, 2025.
Karen Burton, current VP and Chief Accounting Officer, will become CFO on August 18, 2025.
Burton's base salary will increase to $600,000, with target bonus of 75% of base salary and equity award of ~$1,134,000.
Board changes: Dr. Jaqueline Kosecoff and Dr. Richard Steeves retired; Louis Shapiro elected to the Board.
2.02 Results of Operations and Financial Condition · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits